First FDA approval for CAR-T cell therapy

The FDA formally approved the first CAR-T cell therapy for leukaemia. The treatment, which goes by the brand name Kymriah, is produced by Novartis. It will treat acute lymphocytic leukaemia (ALL), a common type of childhood cancer. Current treatments achieve remission rates of 85%. Kymriah is a new therapy for those patients who do not respond to standard treatments or who have relapsed. CAR-T cell therapies for other types of leukaemia are being developed and the treatment is currently also being explored for sold tumours.

 

 

https://www.reuters.com/article/us-novartis-fda/novartis-gene-therapy-approval-signals-new-cancer-treatment-era-idUSKCN1BA1ZY

icons

Registration for the 25th Anniversary Congress is now open

Congress Rates

Academic member €650
Academic non-member €880
Industry member €980
Industry non-member €1290
Student member €310

*Student registrations include complimentary ESGCT Membership

Becoming an ESGCT Academic or Industry member can save you up to 30% on Non-member congress rates

Please see here for full rates including Workshops

REGISTER HERE